此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

HIV 感染者接受 ATI 诱导 VRC01 谱系抗体的免疫研究

426c.Mod.Core-C4b 佐以 3M-052-AF + 明矾免疫联合抗逆转录病毒分析治疗中断 (ATI),在 HIV 感染者中诱导 VRC01 谱系抗体

This is a multicenter controlled interventional trial. This phase 1 trial is the first study to assess 426c.Mod.Core-C4b adjuvanted with 3M-052-AF + aluminum hydroxide suspension (Alum) in people living with HIV (PLWH).

研究概览

详细说明

The aim of this study is to combine the ability of germline (GL)-targeting HIV-1 Envelope protein (Env)-derived immunogens to activate naïve B cells that express the unmutated GL forms of VRC01-class broadly neutralizing antibodies (bnAbs) with the booster capabilities of viral Envs that are expected to circulate in persons living with chronic HIV. The goals are: 1) to elicit VRC01-class GL and intermediate stage antibody responses in PLWH; 2) to identify the viral Envs that guided the maturation of the GL-VRC01 responses elicited by the GL-targeting Env immunogen; 3) during the time when viremia is detectable, the investigator will assess the stage of maturation of these VRC01 antibodies and if they affect viral replication; and 4) investigate how the virus may evolve to escape the activity of these antibodies.

研究类型

介入性

注册 (实际的)

35

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294-2170
        • Alabama CRS (Site # 31788)
    • Georgia
      • Atlanta、Georgia、美国、30303
        • The Ponce de Leon Center CRS (Site # 5802)
      • Decatur、Georgia、美国、30030
        • The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • BIDMC VCRS (Site # 32077)
    • New York
      • New York、New York、美国、10032
        • Columbia P&S CRS (Site # 30329)
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburg CRS (Site # 1001)
    • Washington
      • Seattle、Washington、美国、98104
        • Seattle Vaccine and Prevention CRS (Site # 30331)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Able and willing to complete the informed consent process, including an Assessment of Understanding (AoU): Volunteer demonstrates an understanding of this study and completes a questionnaire prior to first vaccination with verbal demonstration of understanding of questionnaire items that were answered incorrectly.

  2. 18 to 55 years old, inclusive, on day of enrollment.

  3. Confirmed HIV infection as documented by medical records or confirmatory HIV testing at screening.

  4. On suppressive ART for at least 48 weeks prior to screening. ART is defined as a combination therapy regimen including at least 1 integrase inhibitor and 1 nucleoside reverse transcriptase inhibitor (such as Dovato™) or 2 nucleoside reverse transcriptase inhibitors plus integrase inhibitors. Changes in ARVs for reasons other than virologic failure (eg, tolerability, simplification, different formulation, drug-drug interaction profile) are allowed within 48 weeks prior to screening and up until 6 weeks prior to screening. A fully active alternative ARV regimen is available, in the opinion of the Investigator, in the event of discontinuation of the current ARV regimen with development of resistance.

  5. Plasma HIV RNA < 50 copies/mL (or lower limit of quantitation [LLOQ]) for at least 48 weeks prior to enrollment. NOTE: At least one viral load measurement within 48 weeks prior to the screening visit and another viral load from the screening prior to enrollment visit must be available for review. Two "blips" (ie, plasma HIV-1 RNA > LLOQ and < 400 copies/mL) are allowed if each blip is preceded and followed by values < LLOQ and if the blip(s) occur(s) more than 24 weeks prior to enrollment.

  6. CD4+ cell count > 450 cells/mm3 and CD4+ cell % ≥ 15% obtained within 40 days prior to enrollment.

  7. Available for clinic follow-up through the last clinic visit, willing to undergo leukapheresis, and willing to be contacted 12 months after the last study-product administration.

  8. Agrees not to enroll in another study of an investigational agent during participation in the trial. If a potential participant is already enrolled in another clinical trial, approvals from the other trial sponsor and the HVTN 807 PSRT are required prior to enrollment into HVTN 807.

  9. In good general health according to the clinical judgment of the site investigator.

  10. Physical examination and laboratory results without clinically significant findings that would interfere with assessment of safety or reactogenicity in the clinical judgement of the site investigator.

  11. Total serum calcium of ≥ 8.5 mg/dL.

  12. Hemoglobin (Hgb):

    • ≥ 10.0 g/dL for volunteers who were assigned female sex at birth (AFAB)
    • ≥ 11.0 g/dL for cisgender volunteers who were assigned male sex at birth (AMAB) and for transgender men who have been on hormone therapy for more than 6 consecutive months
    • ≥ 11.0 g/dL for transgender women who have been on hormone therapy for more than 6 consecutive months
    • For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine Hgb eligibility based on their sex assigned at birth.
  13. Absolute neutrophil count (ANC) ≥ 750/mm3

    .

  14. Platelets ≥ 100,000/mm3

    .

  15. Alanine aminotransferase (ALT) < 2.5 x upper limit of normal (ULN) based on the institutional normal range and direct bilirubin within the institutional range of normal.

  16. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation.

  17. For Group 1 volunteers: must agree to consistently use condoms from study week 14 through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).

  18. For Group 1 volunteers

    • Persons of pregnancy potential

      • Must have a negative beta human chorionic gonadotropin (β-HCG) pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of contraception from at least 21 days prior to enrollment until at least 8 weeks post last vaccination and viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through until viral load post-ATI is undetectable (at a minimum 20 weeks on study, at a maximum 64 weeks on study).

  19. For Group 2 volunteers

    • Persons of pregnancy potential:

      • Must have a negative β-HCG pregnancy test (urine or serum) on day of enrollment.
      • Must agree to use effective means of contraception from at least 21 days prior to enrollment until 8 weeks after their last scheduled vaccination (study week 20).
    • Volunteers who are AFAB or intersex at birth must agree to not seek pregnancy through alternative methods, such as oocyte retrieval, artificial insemination, or in vitro fertilization from at least 21 days prior to enrollment through 8 weeks after their last scheduled vaccination timepoint.

Exclusion Criteria:

  1. Current receipt of ART other than nucleoside reverse transcriptase inhibitor and integrase inhibitor.

  2. Receipt of long-acting ART within 3 months of enrollment.

  3. Documented history of resistance to any components of the current ARV regimen.

  4. Known resistance to 1 or more drugs in 2 or more ARV drug classes. NOTE: M184V/I is an exception and should not be considered when assessing this criterion. Prior HIV resistance testing is not required.

  5. ART initiation during acute HIV-1 infection (defined as within 1 year of HIV-1 acquisition, if known).

  6. History of an HIV-associated malignancy (including Kaposi's sarcoma), and any type of lymphoma or virus-associated cancers.

  7. History of HIV-associated neurocognitive disease or progressive multifocal leukoencephalopathy.

  8. History of HIV-related illness under US Centers for Disease Control (CDC) Category C (except for recurrent pneumonia) within 10 years prior to screening, based on available medical history and assessed by the Investigator for clinical relevance. Anyone with a history of CD4 < 200 cells/mm3 on one or more occasions, based on available medical history and assessed by the Investigator for clinical relevance. Documentation of every case with history of CD4 < 200 cells/mm3 must be provided to the Sponsor and PSRT, who will determine eligibility on a case-by-case basis. NOTE: History of treated and resolved pulmonary tuberculosis (TB) will not be exclusionary.

  9. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery within 36 months prior to enrollment or for whom such therapies are expected in the subsequent 12 months. NOTE: Minor surgical removal of localized skin cancers (squamous cell carcinoma, basal cell carcinoma) is not exclusionary.

  10. Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg), hepatitis C antibody without documented history of prior treatment and clearance, or hepatitis C virus RNA (HCV-RNA) in blood.

  11. Diagnosis of cirrhosis.

  12. Current untreated or incompletely treated active TB disease or untreated latent TB infection. NOTE: Individuals who are on treatment for latent TB with at least 4 weeks of treatment completed are not excluded.

  13. Volunteer who is breastfeeding or pregnant.

  14. Body mass index (BMI) ≥ 40. Enrollment of individuals with BMI ≥ 40, whom the site investigator assesses are in good health, may be considered by PSRT approval.

  15. Diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c ≤ 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered by the PSRT on a case-by-case basis

  16. History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, including a previous diagnosis of any of the following:

    • Acute myocardial infarction
    • Acute coronary syndromes
    • Stable or unstable angina
    • Coronary or other arterial revascularization
    • Stroke
    • Transient ischemic attack
    • Peripheral arterial disease presumed to be of atherosclerotic origin
  17. Previous or current recipient of an investigational HIV vaccine (previous placebo/control recipients are not excluded).

  18. Receipt of non-HIV experimental vaccine(s) received within the last 1 year. Exceptions include vaccines that have subsequently undergone licensure or Emergency Use Authorization (EUA) by the FDA or World Health Organization (WHO) emergency use listing (EUL), or if outside the US, by the national Regulatory Authority (RA) authorizing this clinical trial.

  19. Congenital or acquired immunodeficiency, including systemic medication use likely to impair immune response to vaccine in the opinion of the site investigator, such as history of systemic corticosteroids (long-term use), immunosuppressive anti-cancer or other immunosuppressive agents, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the investigator within the 24 weeks prior. Note: HIV is not exclusionary.

  20. Blood products or immunoglobulin within 16 weeks prior to enrollment; receipt of immunoglobulin within 16 weeks prior to enrollment requires PSRT approval.

  21. Previous receipt of any anti-HIV monoclonal antibody.

  22. Receipt of any of the following vaccines within 4 weeks prior to enrollment:

    • Live replicating vaccines
    • Any mRNA-based vaccine with FDA licensure, FDA EUA, or WHO EUL
    • ACAM2000 vaccine > 30 days prior with a vaccination scab still present.
  23. Receipt of any vaccines that are not covered in #22 above within 14 days prior to enrollment. Please note this includes replication incompetent vaccines such as the Jynneos vaccine for the prevention of mpox (formerly known as monkeypox) disease.

  24. Initiation of antigen-based immunotherapy (AIT) for allergies within the previous year (stable immunotherapy is not exclusionary); inclusion of participants who initiated immunotherapy within the previous year requires PSRT approval. Note: Any AIT should be scheduled at least 14 days prior to enrollment.

  25. Receipt of investigational research agents with a half-life of 7 or fewer days within 4 weeks prior to enrollment. If a potential participant has received investigational agents with a half-life of greater than 7 days (or unknown half-life) within the past year, PSRT approval is required for enrollment.

  26. History of serious reaction (eg, hypersensitivity, anaphylaxis) to any vaccine or component of the study vaccine, including imidazoquinolone (eg, imiquimod).

  27. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.

  28. Idiopathic urticaria within the past year.

  29. Bleeding disorder diagnosed by a clinician which would make study procedures a contraindication (eg, factor deficiency, coagulopathy, platelet disorder requiring special precautions).

  30. Seizure disorder; febrile seizures as a child or seizures secondary to alcohol withdrawal more than 5 years ago are not exclusionary.

  31. Asplenia or functional asplenia.

  32. Active duty and reserve US military personnel.

  33. Any other chronic or clinically significant condition that, in the clinical judgment of the investigator, would jeopardize the safety or rights of the study participant, including but not limited to: clinically significant forms of substance use or alcohol use disorder(s), serious psychiatric disorders, persons with any suicide attempt within the past 1 year (if between 1 and 2 years, consult PSRT for approval), or cancer that, in the clinical judgement of the site investigator, has potential for recurrence (excluding basal cell carcinoma).

  34. A participant with a history of a potential immune-mediated medical condition (PIMMC), either active or remote. Specific examples are listed in Appendix I (AESI Index). Not exclusionary: 1) Remote history of Bell's palsy (> 2 years ago) not associated with other neurologic symptoms and 2) mild psoriasis that does not require ongoing systemic treatment.

  35. Investigator concern for difficulty with venous access based on clinical history and physical examination. For example, persons with a history of intravenous drug use or substantial difficulty with previous blood draws.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Group 1 (ATI)

Group 1 will receive 2 doses of the vaccine at Week 0 and 12. Group 1 will transition to Schedule 2 at the Week 14 visit. The Schedule 2 "ATI with Monitoring" phase can last for 24 weeks OR until any antiretroviral therapy (ART) re-initiation criteria are met, OR the ATI can continue longer with the approval of the Protocol Safety Review Team (PSRT) and the participant's primary HIV healthcare provider. Group 1 will transition to Schedule 3, the "Follow-up on ART restart" phase that lasts until study week 64, regardless of the point where it begins.

100 mcg and 300 mcg

5 mcg

实验性的:Group 2 (No ATI) Control

Group 2 transitions from Schedule 1 into Schedule 4, "Follow-up on ART," at the Week 14 visit, and remains on Schedule 4 through study week 64.

100 mcg and 300 mcg

5 mcg

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
参与者局部反应原性体征和症状的数量
大体时间:每次疫苗接种后 14 天
每次疫苗接种后 14 天
参与者全身反应原性体征和症状的数量
大体时间:每次疫苗接种后 14 天
每次疫苗接种后 14 天
Number and description of serious adverse events (SAEs)
大体时间:12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of medically attended adverse events (MAAEs)
大体时间:12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of adverse events of special interest (AESIs)
大体时间:12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Number and description of AEs leading to early participant withdrawal or permanent discontinuation and reason for withdrawal/discontinuation
大体时间:12 months following any receipt of study product

adverse events (AEs) will be graded according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult AEs

12 months following any receipt of study product
Frequency of total Env-specific and CD4-bs-specific B cells, prior to ATI
大体时间:At baseline (week 0) and after each vaccination

as assessed by flow cytometry at baseline and after each vaccination

At baseline (week 0) and after each vaccination
Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells, prior to ATI
大体时间:At baseline (week 0) and after each vaccination

, as assessed by B-cell sorting and BCR sequencing

At baseline (week 0) and after each vaccination
Frequency of Env-specific and CD4-bs-specific B cells
大体时间:After week 16

as assessed by flow cytometry

After week 16
Frequency of VRC01-class BCR sequences of isolated CD4-bs B cells
大体时间:After week 16

as assessed by B-cell sorting and BCR sequencing

After week 16

次要结果测量

结果测量
大体时间
比较 ATI 期间启动 VRC01 抗体开发和未开发 VRC01 抗体的第 1 组参与者的 Env 序列
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
来自第一组参与者的选定recEnv的结合程度,该组参与者启动了VRC01类抗体到VRC01类前体和中间体抗体的开发
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
来自第 1 组参与者的选定 recEnv 的结合程度,这些参与者启动了针对表达 VRC01 类 BCR 的 B 细胞的 VRC01 类抗体的开发。
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月

其他结果措施

结果测量
大体时间
研究期间分离的任何 VRC01 类抗体的结合和中和活性的大小
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
第 2 组参与者的病毒序列(如果研究中出现任何病毒)与第 1 组参与者的病毒序列出现相似性的频率
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
参与者和潜在参与者的动机、对 ATI、长期病毒血症和试验要求的认知和耐受性(例如 ART 转换、所有性活动的屏障保护)
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
社会效益的大小(例如利他主义)和负面社会影响,包括但不限于对停止抗逆转录病毒疗法和再次感染病毒的焦虑以及对无意中将艾滋病毒传播给伴侣的恐惧
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
参与者和潜在参与者决策质量的程度,包括知情感、决策的清晰度和支持,以及对参与选择的满意度。
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
每种疫苗方案的免疫原性反应率,可以在一部分参与者中进行额外的病毒学和免疫原性测定,包括其他时间点的样本
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月
进行与进一步了解艾滋病毒、免疫学、疫苗和临床试验进行相关的分析
大体时间:研究持续时间或收到研究产品后 12 个月
研究持续时间或收到研究产品后 12 个月

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年1月3日

初级完成 (实际的)

2026年10月12日

研究完成 (实际的)

2026年10月12日

研究注册日期

首次提交

2023年8月17日

首先提交符合 QC 标准的

2023年8月17日

首次发布 (实际的)

2023年8月23日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • HVTN 807
  • 39013 (其他标识符:DAIDS Document ID)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅